PL2455381T3 - Triazolopirydynowy związek i jego działanie jako inhibitora hydroksylazy prolinowej i środka indukującego wytwarzanie erytropoetyny - Google Patents

Triazolopirydynowy związek i jego działanie jako inhibitora hydroksylazy prolinowej i środka indukującego wytwarzanie erytropoetyny

Info

Publication number
PL2455381T3
PL2455381T3 PL10799914T PL10799914T PL2455381T3 PL 2455381 T3 PL2455381 T3 PL 2455381T3 PL 10799914 T PL10799914 T PL 10799914T PL 10799914 T PL10799914 T PL 10799914T PL 2455381 T3 PL2455381 T3 PL 2455381T3
Authority
PL
Poland
Prior art keywords
eritropoetin
inductive
inhibitor
activity
production
Prior art date
Application number
PL10799914T
Other languages
English (en)
Polish (pl)
Inventor
Ikuo Mitani
Yosuke Ogoshi
Takuya Matsui
Masahiro Yokota
Masakazu Terashita
Dai Motoda
Kazuhito Ueyama
Hiroyuki Abe
Takahiro Hotta
Takashi Ito
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of PL2455381T3 publication Critical patent/PL2455381T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
PL10799914T 2009-07-17 2010-07-16 Triazolopirydynowy związek i jego działanie jako inhibitora hydroksylazy prolinowej i środka indukującego wytwarzanie erytropoetyny PL2455381T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2009169565 2009-07-17
US27312709P 2009-07-30 2009-07-30
EP10799914.6A EP2455381B9 (en) 2009-07-17 2010-07-16 Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
PCT/JP2010/062037 WO2011007856A1 (ja) 2009-07-17 2010-07-16 トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用

Publications (1)

Publication Number Publication Date
PL2455381T3 true PL2455381T3 (pl) 2014-10-31

Family

ID=43449466

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10799914T PL2455381T3 (pl) 2009-07-17 2010-07-16 Triazolopirydynowy związek i jego działanie jako inhibitora hydroksylazy prolinowej i środka indukującego wytwarzanie erytropoetyny

Country Status (28)

Country Link
US (3) US8283465B2 (enExample)
EP (3) EP2455381B9 (enExample)
JP (9) JP5021797B2 (enExample)
KR (5) KR20260012830A (enExample)
CN (1) CN102471337B (enExample)
AR (1) AR077417A1 (enExample)
AU (1) AU2010271732B2 (enExample)
BR (1) BR112012001157A2 (enExample)
CA (1) CA2768505C (enExample)
CO (1) CO6430426A2 (enExample)
DK (1) DK2455381T5 (enExample)
ES (1) ES2477968T3 (enExample)
HR (1) HRP20140705T1 (enExample)
IL (1) IL217541A (enExample)
ME (1) ME01858B (enExample)
MX (1) MX2012000766A (enExample)
MY (1) MY160814A (enExample)
NZ (1) NZ598242A (enExample)
PE (1) PE20120629A1 (enExample)
PL (1) PL2455381T3 (enExample)
PT (1) PT2455381E (enExample)
RS (1) RS53499B1 (enExample)
RU (1) RU2538963C2 (enExample)
SG (1) SG178049A1 (enExample)
SI (1) SI2455381T1 (enExample)
SM (1) SMT201500122B (enExample)
TW (1) TWI485150B (enExample)
WO (1) WO2011007856A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2455381E (pt) * 2009-07-17 2014-06-24 Japan Tobacco Inc Composto de triazolopiridina e sua acção como inibidor da prolil-hidroxilase e indutor da produção de eritropoietina
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
CN104936591B (zh) 2012-11-26 2018-05-29 国立大学法人东北大学 促红细胞生成素表达增强剂
NZ708605A (en) 2012-12-24 2016-07-29 Cadila Healthcare Ltd Novel quinolone derivatives
SMT202400092T1 (it) 2013-06-13 2024-05-14 Akebia Therapeutics Inc Composizioni e metodi per il trattamento dell'anemia
RU2534804C1 (ru) * 2013-08-05 2014-12-10 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ, ПРОЯВЛЯЮЩИЕ СВОЙСТВА АНТАГОНИСТОВ АДЕНОЗИНОВЫХ А2А РЕЦЕПТОРОВ, И ИХ ПРИМЕНЕНИЕ
SMT201800205T1 (it) 2013-10-03 2018-05-02 Kura Oncology Inc Inibitori di erk e metodi d'uso
WO2016034108A1 (zh) 2014-09-02 2016-03-10 广东东阳光药业有限公司 喹啉酮类化合物及其应用
JP2018039733A (ja) * 2014-12-22 2018-03-15 株式会社富士薬品 新規複素環誘導体
GB201504565D0 (en) * 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
CN106146395B (zh) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
EP4667059A3 (en) 2015-05-28 2026-04-08 Japan Tobacco Inc. Method for treating or preventing diabetic nephropathy
RU2752384C2 (ru) * 2016-11-25 2021-07-26 Джапан Тобакко Инк. Способ получения триазолопиридинового соединения
CA3062972C (en) 2017-05-09 2021-09-14 Kind Pharmaceutical Indolizine derivatives and their application in medicine
WO2019069973A1 (ja) * 2017-10-04 2019-04-11 日本たばこ産業株式会社 含窒素ヘテロアリール化合物およびその医薬用途
CN107739378A (zh) * 2017-11-14 2018-02-27 杭州安道药业有限公司 吲哚嗪衍生物及其在医药上的应用
PL3808747T3 (pl) * 2018-09-13 2025-03-17 Kissei Pharmaceutical Co., Ltd. Związek imidazopirydynonowy
CN110105355B (zh) * 2019-05-24 2021-09-21 烟台大学 一种1,2,3-三唑-[1,5-a]并喹啉类化合物的制备方法
JP7566008B2 (ja) * 2020-03-11 2024-10-11 キッセイ薬品工業株式会社 イミダゾピリジノン化合物又はその塩の結晶
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN113387948B (zh) * 2021-02-06 2022-06-10 成都诺和晟泰生物科技有限公司 一种稠环杂芳基衍生物及其药物组合物和治疗方法及用途
EP4308120A4 (en) 2021-03-19 2024-11-27 Zydus Lifesciences Limited TREATMENT OF SICKLE CELL ANEMIA
WO2022251563A1 (en) 2021-05-27 2022-12-01 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
CN113582843A (zh) * 2021-09-09 2021-11-02 无锡捷化医药科技有限公司 一种5-氯-2-氟-3-羟基苯甲酸乙酯的制备方法
CN116496269B (zh) * 2021-12-02 2025-02-28 苏中药业集团股份有限公司 一种脯氨酰羟化酶抑制剂及其用途
CN114031619A (zh) * 2021-12-17 2022-02-11 山东汇海医药化工有限公司 一种图卡替尼中间体的制备方法
CN117327066A (zh) * 2022-06-30 2024-01-02 上海济煜医药科技有限公司 一种新多晶型、其制备方法及其用于制备药物的用途
EP4578855A1 (en) * 2022-09-19 2025-07-02 Suzhong Pharmaceutical Group Co., Ltd. Prolyl hydroxylase inhibitor and use thereof
TWI905781B (zh) * 2023-06-02 2025-11-21 大陸商蘇中藥業集團股份有限公司 脯胺醯羥化酶抑制劑及其用途
TW202506675A (zh) * 2023-08-08 2025-02-16 美商富曼西公司 用於防治和對抗無脊椎有害生物的連接的雙環化合物
WO2025087207A1 (zh) 2023-10-24 2025-05-01 杭州安道药业有限公司 含有缺氧诱导因子-脯酰胺羟基化酶抑制剂的长效口服药物及其应用
CN117486878B (zh) * 2023-10-27 2026-05-05 扬州市普林斯医药科技有限公司 一种恩那司他的制备方法
WO2025137158A1 (en) * 2023-12-19 2025-06-26 Akebia Therapeutics, Inc. Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as phd inhibitor compounds, compositions, and methods of use
CN119818492B (zh) * 2024-02-05 2026-01-30 深圳信立泰药业股份有限公司 化合物在制备治疗非髓系恶性肿瘤患者的贫血药物中的应用
WO2025167739A1 (zh) * 2024-02-05 2025-08-14 深圳信立泰药业股份有限公司 化合物在制备预防和/或治疗高原病的药物中的应用
CN119039291A (zh) * 2024-09-09 2024-11-29 南京药坦生物科技有限公司 一种恩那度司他中间体及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US6355653B1 (en) * 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
BR0213172A (pt) * 2001-10-08 2004-09-14 Hoffmann La Roche Amida do ácido 8-amino-[1,2,4]triazolo[1,5-a]piridina-6-carboxìlico
WO2005014533A2 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
EP1776338A1 (en) * 2004-08-05 2007-04-25 F. Hoffmann-Roche AG Indole, indazole or indoline derivatives
FR2889383A1 (fr) * 2005-08-01 2007-02-02 France Telecom Procede et dispositif de detection pour systeme mimo, systeme mimo, programme et support d'information
AR059733A1 (es) * 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
WO2007136990A2 (en) * 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JO2934B1 (en) * 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
NZ601730A (en) * 2006-06-26 2014-04-30 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
US20100035756A1 (en) 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
TW200845991A (en) * 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
EP2142509B1 (en) * 2007-04-18 2013-12-04 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
WO2008137084A2 (en) 2007-05-04 2008-11-13 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
EP2460787A1 (en) 2007-07-03 2012-06-06 Astellas Pharma Inc. Amide compounds and their use as PGE2 antagonists.
US20100305154A1 (en) * 2007-11-30 2010-12-02 Glaxosmithkline Llc Prolyl Hydroxylase Inhibitors
WO2009073497A2 (en) * 2007-11-30 2009-06-11 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009126624A1 (en) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
WO2009134850A1 (en) * 2008-04-30 2009-11-05 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
AU2009251324A1 (en) 2008-05-29 2009-12-03 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators
SG172206A1 (en) 2008-12-19 2011-07-28 Leo Pharma As Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
PT2455381E (pt) * 2009-07-17 2014-06-24 Japan Tobacco Inc Composto de triazolopiridina e sua acção como inibidor da prolil-hidroxilase e indutor da produção de eritropoietina

Also Published As

Publication number Publication date
NZ598242A (en) 2013-09-27
KR20120051704A (ko) 2012-05-22
SMT201500122B (it) 2015-07-09
KR20170018105A (ko) 2017-02-15
JP2016040321A (ja) 2016-03-24
EP2455381B9 (en) 2014-10-22
CO6430426A2 (es) 2012-04-30
JP2011037841A (ja) 2011-02-24
RU2538963C2 (ru) 2015-01-10
AU2010271732B2 (en) 2016-08-25
EP2455381B1 (en) 2014-05-28
SG178049A1 (en) 2012-03-29
JP2022126843A (ja) 2022-08-30
CA2768505C (en) 2018-06-12
CN102471337B (zh) 2014-12-10
KR101850661B1 (ko) 2018-04-19
EP3594213A1 (en) 2020-01-15
AR077417A1 (es) 2011-08-24
WO2011007856A1 (ja) 2011-01-20
TW201105671A (en) 2011-02-16
AU2010271732A1 (en) 2012-03-08
JP2024091878A (ja) 2024-07-05
US20130096155A1 (en) 2013-04-18
JP2017214404A (ja) 2017-12-07
DK2455381T3 (da) 2014-07-21
CN102471337A (zh) 2012-05-23
CA2768505A1 (en) 2011-01-20
ES2477968T3 (es) 2014-07-18
IL217541A0 (en) 2012-02-29
ME01858B (me) 2014-12-20
JP2015003933A (ja) 2015-01-08
EP2455381A1 (en) 2012-05-23
IL217541A (en) 2014-07-31
HK1168346A1 (en) 2012-12-28
EP2746282A1 (en) 2014-06-25
JP6434575B2 (ja) 2018-12-05
MY160814A (en) 2017-03-31
PE20120629A1 (es) 2012-05-30
ES2477968T9 (es) 2014-11-13
KR20260012830A (ko) 2026-01-27
KR20180042443A (ko) 2018-04-25
KR20230165366A (ko) 2023-12-05
US8283465B2 (en) 2012-10-09
PT2455381E (pt) 2014-06-24
RS53499B1 (sr) 2015-02-27
BR112012001157A2 (pt) 2016-02-23
US20110077267A1 (en) 2011-03-31
EP2455381A4 (en) 2012-12-12
RU2012105467A (ru) 2013-08-27
SI2455381T1 (sl) 2014-08-29
HRP20140705T1 (hr) 2014-09-12
KR101706803B1 (ko) 2017-02-14
JP5021797B2 (ja) 2012-09-12
MX2012000766A (es) 2012-02-08
DK2455381T5 (en) 2015-02-09
US20160145254A1 (en) 2016-05-26
JP2012144571A (ja) 2012-08-02
JP2019019144A (ja) 2019-02-07
TWI485150B (zh) 2015-05-21
JP2020111612A (ja) 2020-07-27

Similar Documents

Publication Publication Date Title
HUS2000005I1 (hu) Diamino-heterociklusos karboxamid-vegyület
SI2455381T1 (sl) Triazolopiridinova spojina in njeno delovanje kot zaviralec prolil-hidroksilaze in induktor produkcije eritropoietina
PL2324831T3 (pl) Terapia pirfenidonem z wykluczeniem fluwoksaminy
PL2504336T3 (pl) Nowe pochodne naftyrydynowe i ich zastosowanie jako inhibitorów kinaz
PL2504332T5 (pl) Amorficzna i krystaliczna postać hemiwinianu genz 112638 jako inhibitor syntazy glukozyloceramidowej
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
EP2444119A4 (en) Magnetic stimulator
CR20120295A (es) Triazolopiridinas
DK2496236T3 (da) Prolylhydroxylasehæmmere
SMT201500262B (it) Trattamento della sclerosi multipla con laquinimod
ZA201404552B (en) Benzoxepin pi3k inhibitor compound and use thereof
IL212762A0 (en) Thiochromene derivatives as hif hydroxylase inhibitors
HUE039731T2 (hu) l,3-difenilprop-2-én-l-on-származékok alkalmazása májbetegségek kezelésére
IL212250A0 (en) Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition
ZA201006719B (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
PL2443105T3 (pl) Nowe pochodne fenyloimidazolu jako inhibitor enzymu PDE10A
EP2398025A4 (en) CONVERTER
EP2519508A4 (en) METALLO ENZYME INHIBITOR COMPOUNDS
EP2413941A4 (en) Renin Inhibitors
FI20096045L (fi) Induktiivisen komponentin käämijärjestely
SI2506840T1 (sl) Uporabe zaviralcev faktorja, ki jih inducira hiposkija
EP2421882A4 (en) ANGIOGENESIS INHIBITORS
EP2447961A4 (en) CONVERTER
BR112013014484A2 (pt) compostos inibidores de metaloenzimas
PL2501520T3 (pl) Magnetyczny uchwyt ustalający